We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ANIFROLUMABE: UMA NOVA ERA NO TRATAMENTO DO LÚPUS ERITEMATOSO SISTÊMICO.
- Authors
Macedo dos Santos, Carla Raquel; de Castro Ulhôa, Maury; Moreira Andrade, Gabriel Duarte; Martins Garcia, Giani
- Abstract
This study evaluated the impact of Anifrolumab in the treatment of Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. The aim was to examine the efficacy, mechanism of action and safety profile of this new therapy. The methodology consisted of a descriptive review of clinical studies, randomized controlled trials, metaanalyses, renowned medical books and Ministry of Health data published between 2016 and 2024. Anifrolumab, a monoclonal antibody that blocks the type I interferon receptor (IFNAR1), has shown efficacy in reducing inflammation, restoring immune function by decreasing the production of autoantibodies and inflammatory cytokines, and controlling SLE activity. The results showed that Anifrolumab is a promising therapeutic option for patients with moderate to severe SLE, providing better disease control and reducing the need for corticosteroids.
- Subjects
TYPE I interferons; SYSTEMIC lupus erythematosus; AUTOIMMUNE diseases; AUTOANTIBODIES; PREVENTIVE medicine
- Publication
Revista Foco (Interdisciplinary Studies Journal), 2024, Vol 17, p1
- ISSN
1981-223X
- Publication type
Article
- DOI
10.54751/revistafoco.ed.esp-004